Vaxdyn
2011
FOUNDED
PRIVATE
STATUS
Seed
LATEST DEAL TYPE
$1.2M
LATEST DEAL AMOUNT
3
INVESTORS
Description
Developer of novel vaccines designed to offer prevention from infectious diseases. The company's vaccines uses antigens, immunomodulators, nanoparticles and mAbs, enabling doctors to decrease the impact on public health of infections caused by drug-resistant pathogens.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- Campus Hospital Universitario Virgen del Rocio
- Av. Manuel Siurot, s/n, Centro de Documentación Clínica
- 41013 Seville
- Spain
+34 606 00 00 00
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Vaxdyn’s full profile, request a free trial.
Vaxdyn Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Seed Round | 01-Jan-2016 | $1.2M | 00.00 | Completed | Startup |
Vaxdyn Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Caixa Capital Risc | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Ministry of Economy | Other | 000 0000 | 000000 0 | |||
| InSynchrony Ventures | Venture Capital | Minority | 000 0000 | 000000 0 |
Vaxdyn Executive Team (3)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Manuel Montoya | Chief Operating Officer | ||
| Michael McConnell Ph.D | Chief Scientific Officer | ||
| Juan Infante Ph.D | Chief Executive Officer & Board Member |
Vaxdyn Board Members (2)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Juan Infante Ph.D | Self | Chief Executive Officer & Board Member | 000 0000 | |
| Pilar Pérez-Romero Ph.D | Vaxdyn | Chairman of the Board | 000 0000 |